Tamoxifen study could boost testing for BRCA1 and BRCA2
This article was originally published in Clinica
Executive Summary
In a study that could encourage more women at high risk of breast cancer to seek genetic testing, researchers have found that the drug, tamoxifen, reduces the incidence of the disease in healthy women with the genetic mutation BRCA2 but does not work in those with the BRCA1 mutation.